[1] Kaliyaperumal K, GroveJI, Delahay RM, et al. Pharmacoge-nomics of drug-induced liver injury (DILI): Molecular biology to clinical applications. J Hepatol, 2018, 69: 948-957.
[2] 中华医学会肝病学分会药物性肝病学组, 药物性肝损伤诊治指南. 肝脏, 2015, 20: 750-767.
[3] 茅益民, 于乐成, 马洪年, 等. 药物性肝病.上海科学技术出版社, 2016, 7-7.
[4] Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther, 2013, 93: 153-158.
[5] Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken), 2012, 64: 1431-1446. |
